.jpg?format=webp&width=780)
Desmoid tumours are rare, locally aggressive, but typically nonmetastatic soft-tissue tumors for which no systemic therapy is currently approved. Although rarely lethal, these fast-growing tumours can lead to substantial comorbidities. Now, data from the phase III DeFi trial demonstrate the efficacy of the γ-secretase inhibitor nirogacestat in patients with progressing desmoid tumours.
Like
Save
Share